Do SGLT2 inhibitors reduce mortality and heart failure hospitalizations in patients with heart failure?
SGLT2 inhibitors provide significant mortality and morbidity benefits in patients with heart failure, consistent across multiple demographic and clinical subgroups.
In patients with HF, SGLT2 inhibitors significantly reduce all-cause and cardiovascular mortality compared with placebo. In addition, the composite of cardiovascular mortality or HF hospitalizations/urgent visits is reduced with SGLT2 inhibitors across subgroups of sex, age, race, eGFR, HF functional class, and ejection fraction.
Cardoso et al. (2021) studied this question.